Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination

Swadźba, Jakub; Anyszek, Tomasz; Panek, Andrzej; Martin, Emilia

doi:10.3390/vaccines9111367

Cited by 13 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, the presence of liver disease or liver cirrhosis showed no correlation with antibody titers or neutralizing activity. Regarding age, our findings are consistent with previously published data on the effect of age on both immunogenicity and subsequent sustainability of humoral responses [25][26][27][28]. This could be partially explained by immunosenescence along with enriched comorbidities in older individuals [29].…”

Section: Discussionsupporting

confidence: 91%

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

Bakasis

Bitzogli

Mouziouras

et al. 2022

Viruses

View full text Add to dashboard Cite

The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination.

show abstract

Section: Discussionsupporting

confidence: 91%

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

Bakasis

Bitzogli

Mouziouras

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…Further improvements focused on antibody specificity [ 10 , 11 , 12 ]. This is particularly important, considering that only the assays based on SARS-CoV-2 spike (S) protein are able to detect the humoral response to the vaccination [ 13 ]. Nucleocapsid-based (N, NCP) kits are not widely used in the vaccination era.…”

Section: Introductionmentioning

confidence: 99%

Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course

Swadźba

Anyszek

Panek³

et al. 2022

Diagnostics

Self Cite

View full text Add to dashboard Cite

The immunoassays used to measure anti-spike SARS-CoV-2 antibodies are widely available on the market. However, their performance in COVID-19 vaccinees is not yet adequately assessed. Our study provides a head-to-head comparison of five methods: Abbott’s S1-RBD IgG, Roche’s S1-RBD total antibody, Euroimmun’s S1 IgG, and DiaSorin’s TrimericS IgG and S1/S2 IgG assays. Testing was performed in one hundred vaccinated subjects, at eight timepoints over eight months after vaccination. The results differed substantially between methods; however, they correlated strongly and demonstrated the individuals’ responses to both doses of vaccination and the waning of humoral immunity after eight months. Importantly, we encountered a high percentage of results above the assay-specific upper quantitation limit (UQL) for undiluted samples. This was the most pronounced for the Roche’s and Euroimmun’s assays. The Abbott’s assay showed the lowest percentage of results above the UQL. We also attempted to find a common way to establish antibody concentrations that might be classified as high. However, this resulted in between 10% and 100% of such results for different methods on day 240′. This highlights the need for an assay-specific approach for adjusting the cut-offs that may indicate COVID-19 immunity.

show abstract

“…Another study by Swadźba et al [11] on the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine reported that the concentration of antibodies significantly decreased between days 90 and 120.…”

Section: Discussionmentioning

confidence: 99%

Sequential Observation of Antibody Response Pattern at 3 and 6 Months Following ChAdOx1 nCoV-19 Vaccination Among Health Care Workers-A Prospective Single Cohort Study

Jose

Bhaskaran²,

V³

et al. 2022

CJHR

View full text Add to dashboard Cite

Background: The duration of the immune response induced by ChAdOx1 nCoV-19 vaccination in a real-world setting is unknown. Objectives: This study is aimed to estimate the 6-month trend of SARS-CoV-2 antibody titer after Covishield vaccination among Health Care workers (HCW) and their associated factors. Materials & Methods: A prospective single cohort study of health care workers was done in a tertiary care-teaching institute of central Kerala from January 2021 to October 2021. HCWs who have given pre-vaccination serum sample for SARS-CoV-2 antibody estimation and negative for SARS-CoV-2 antibody were included. They were followed up and their blood samples to check for antibody levels were taken 28 days after first dose, 2 weeks after second dose, and 3 and 6 months after first dose of ChAdOx1 nCoV-19 vaccine. Samples taken from 102 HCW were sent for SARS-CoV-2 IgG antibody testing. Results: Mean age of the study participants was 39.3 (age range:19 - 71) yrs. and 71.6% were females. Antibody levels of participants at 3rd month ranged from 0.28 S/C to 21.2 S/C with a mean of 8.01. Only 34 (33.3%) HCW had IgG antibody levels >9.5 S/C. Mean antibody level further declined to 6.09 S/C at 6th month. Only 19 (28.4%) had antibody levels more than 9.5 S/C at 6th month. HCW with aged less than 50 years and those who had COVID disease during the study period had a significantly higher level of IgG antibody titres. Quantitative results were reported as signal to cut-off (S/C) value. Conclusion: The study found that after vaccination with Covishield vaccine IgG levels peaked at 14 days following second dose of vaccine, then getting decreased in the third month and further in sixth month confirming the need for a booster dose. COVID antibody levels were significantly higher in COVID infected HCW and in young age participants

show abstract

Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination

Cited by 13 publications

References 33 publications

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course

Sequential Observation of Antibody Response Pattern at 3 and 6 Months Following ChAdOx1 nCoV-19 Vaccination Among Health Care Workers-A Prospective Single Cohort Study

Contact Info

Product

Resources

About